Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
Ticker SymbolEOLS
Company nameEvolus Inc
IPO dateFeb 08, 2018
CEOMr. David Moatazedi
Number of employees332
Security typeOrdinary Share
Fiscal year-endFeb 08
Address520 Newport Center Dr Ste 1200
CityNEWPORT BEACH
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code92660-7022
Phone19492844555
Websitehttps://www.evolus.com/
Ticker SymbolEOLS
IPO dateFeb 08, 2018
CEOMr. David Moatazedi
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data